相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease
Mario Cottone et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Increased Risk of Nonmelanoma Skin Cancers Among Individuals With Inflammatory Bowel Disease
Harminder Singh et al.
GASTROENTEROLOGY (2011)
Cancer in Crohn's Disease Patients Treated with Infliximab: A Long-term Multicenter Matched Pair Study
Livia Biancone et al.
INFLAMMATORY BOWEL DISEASES (2011)
Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice
Y. Zabana et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease
R. Panaccione et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Increased Risk for Non-Melanoma Skin Cancer in Patients With Inflammatory Bowel Disease
Millie D. Long et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months
Gary R. Lichtenstein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
AGA Technical Review on the Diagnosis and Management of Colorectal Neoplasia in Inflammatory Bowel Disease
Francis A. Farraye et al.
GASTROENTEROLOGY (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Risk of Lymphoma Associated With Combination Anti-Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
Corey A. Siegel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Risk of Cervical Abnormalities in Women With Inflammatory Bowel Disease: A Population-Based Nested Case-Control Study
Harminder Singh et al.
GASTROENTEROLOGY (2009)
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study
H. Fidder et al.
GUT (2009)
Higher Incidence of Abnormal Pap Smears in Women With Inflammatory Bowel Disease
Sunanda Kane et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Infliximab for Inflammatory Bowel Disease in Denmark 1999-2005: Clinical Outcome and Follow-Up Evaluation of Malignancy and Mortality
Sarah Caspersen et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials
Laurent Peyrin-Biroulet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Serious Events with Infliximab in Patients with Inflammatory Bowel Disease A 9-Year Cohort Study in the Netherlands
Hilbert S. de Vries et al.
DRUG SAFETY (2008)
Endoscopic ultrasound delivery of an antitumor agent to treat a case of pancreatic cancer
Kenneth J. Chang et al.
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY (2008)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Maintenance therapy with certolizumab pegol for Crohn's disease
Stefan Schreiber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Abnormalities of uterine cervix in women with inflammatory bowel disease
Jyoti Bhatia et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
T Bongartz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study
L Biancone et al.
GUT (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Haematopoietic malignancies in rheumatoid arthritis:: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
J Askling et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Risk of haematopoietic cancer in patients with inflammatory bowel disease
J Askling et al.
GUT (2005)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients
JF Colombel et al.
GASTROENTEROLOGY (2004)
Life and death decisions: Secondary complexes and lipid rafts in TNF receptor family signal transduction
JR Muppidi et al.
IMMUNITY (2004)
Signalling pathways of the TNF superfamily: A double-edged sword
BB Aggarwal
NATURE REVIEWS IMMUNOLOGY (2003)
Current uses of isolated limb perfusion in the clinic and a model system for new strategies
AMM Eggermont et al.
LANCET ONCOLOGY (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Inflammatory bowel disease is not associated with an increased risk of lymphoma
JD Lewis et al.
GASTROENTEROLOGY (2001)
分享论文
